Foley & Lardner LLP partner Louis Lehot shared insights on the factors fueling the biotech IPO rebound in the Mergermarket article, “Biotech IPO window widens as M&A fuels 2026 revival.”
Lehot noted that large pharmaceutical companies facing patent expirations are increasingly turning to acquisitions to replenish their pipelines.
“Once a drug demonstrates commercial potential, larger drugmakers can provide the sales and marketing infrastructure needed to scale the product and may ultimately acquire the developer, either before or after an IPO,” he said.
People
Related News
November 20, 2026
In the News
Louis Lehot Highlights Governance Challenges for Founder-Controlled Companies
Foley & Lardner LLP partner Louis Lehot authored the Law360 article, “Cloudflare Ruling Leaves Founder-Control Plans On Thin Ice,” examining the implications of the Delaware Court of Chancery’s recent Cloudflare ruling.
November 19, 2026
In the News
Susan Poll Klaessy Shares Her People-First Approach to Practice Leadership – 'Truly invest in people'
Foley & Lardner LLP partner Susan Poll Klaessy shares insights on leadership, client service, and developing talent in Law.com's “How I Made Practice Group Chair” series.
November 17, 2026
In the News
Brian Wheeler Comments on Private Equity Co-Investment Trends
Foley & Lardner LLP partner Brian Wheeler was featured in the PitchBook article “Middle-market funds are pulling in more LP money thanks to co-investments,” highlighting the growing role of co-investments in private equity fundraising and the opportunities they provide to limited partners (LPs).